Viviana Cardoso-Pérez

Viviana Cardoso-Pérez

Auto-generated profile, based on publicly available information

Viviana Cardoso-Pérez

AlergiaMx Mexico City Mexico

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
JFJenyfer María Fuentes-Mendoza
Jenyfer María Fuentes-Mendoza
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
JMJuan Munoz-Moreno
Juan Munoz-Moreno
LCLuis Concepción-Urteaga
Luis Concepción-Urteaga
JIJosé Paz Ibarra
José Paz Ibarra
VCViviana Cardoso-Pérez
Viviana Cardoso-Pérez

26 October 2026 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
SMSebastian Moreno‐Castro
Sebastian Moreno‐Castro
VCViviana Cardoso‐Perez
Viviana Cardoso‐Perez
DMDiego A Mares‐Mateos
Diego A Mares‐Mateos
MPMariel Paez‐Reyes
Mariel Paez‐Reyes
PAPaola de Baro Alvarez
Paola de Baro Alvarez
Background: Allergen immunotherapy (AIT) may modify allergic respiratory disease, but its association with progression and remission in routine practice remains uncertain. Materials and Methods: We emulated a target trial in a single‐center retrospective cohort at AlergiaMx, Mexico City, using data from 2020 to 2025. We compared sublingual allergen immunotherapy initiation within a 14‐day grace period with non‐initiation among AIT‐eligible patients. Follow‐up extended up to 36 months, and propensity‐score overlap weighting addressed baseline confounding. Results: Among 2,713 patients, 1,971 initiated AIT and 742 did not. Weighted disease worsening was 46.3% versus 63.6% (relative risk [RR] 0.73, 95% confidence interval [CI] 0.65–0.82), and sustained progression was 8.4% versus 17.0% (RR 0.49, 95% CI 0.35–0.69). At 36 months, clinical remission was 47.0% versus 18.3% (RR 2.57, 95% CI 1.93–3.43), and treatment‐associated remission was 31.7% versus 5.8% (RR 5.44, 95% CI 3.23–9.16). Longitudinal differences favored AIT for asthma control, quality of life, and fractional exhaled nitric oxide. Discussion: AIT initiation was associated with less worsening, greater remission, and favorable clinical and inflammatory trajectories over 36 months. These observational findings do not establish a causal disease‐modifying effect; residual confounding and differential follow‐up remain possible.